{"id":49660,"date":"2025-12-01T23:15:03","date_gmt":"2025-12-01T15:15:03","guid":{"rendered":"https:\/\/flcube.com\/?p=49660"},"modified":"2025-12-01T23:15:04","modified_gmt":"2025-12-01T15:15:04","slug":"humanwells-hws117-long-acting-fsh-secures-nmpa-clinical-trial-approval-for-assisted-reproduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49660","title":{"rendered":"Humanwell&#8217;s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction"},"content":{"rendered":"\n<p><strong>Humanwell Healthcare (Group) Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600079:SHA\">SHA: 600079<\/a>) announced that its <strong>Class\u202f1 biological product HWS117 injection<\/strong> has received <strong>clinical trial approval<\/strong> from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>controlled ovarian stimulation<\/strong> in assisted reproductive technology (ART).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-approval-amp-indication\">Clinical Trial Approval &amp; Indication<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>HWS117 injection<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>Category\u202f1 therapeutic biological product<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Controlled ovarian stimulation to promote multi\u2011follicular development in ART<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA clinical trial approval received<\/td><\/tr><tr><td><strong>Key Advantage<\/strong><\/td><td>Novel <strong>long\u2011acting FSH<\/strong> to reduce injection frequency and improve patient compliance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovation\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: HWS117 is a <strong>long\u2011acting follicle\u2011stimulating hormone (FSH)<\/strong> designed to extend half\u2011life in vivo, reducing dosing burden versus conventional short\u2011acting FSH products.<\/li>\n\n\n\n<li><strong>Development Platform<\/strong>: Proprietary protein engineering platform designed to enhance FSH pharmacokinetics while maintaining biological activity.<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: For decades, China\u2019s assisted reproduction market has been dominated by short\u2011acting FSH drugs requiring daily injections; long\u2011acting alternatives aim to improve treatment adherence and clinical workflow efficiency.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-landscape-amp-competitive-position\">Market Landscape &amp; Competitive Position<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product Type<\/th><th>Status in China<\/th><th>Clinical Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Short\u2011acting FSH<\/strong><\/td><td>Market dominant (legacy standard)<\/td><td>Daily injections, higher patient burden<\/td><\/tr><tr><td><strong>Long\u2011acting FSH (Class\u202f3.2)<\/strong><\/td><td><strong>2 approved<\/strong> for marketing<\/td><td>Reduced injection frequency<\/td><\/tr><tr><td><strong>Long\u2011acting FSH (Class\u202f1)<\/strong><\/td><td><strong>3 approved for trials<\/strong> (including HWS117)<\/td><td>Novel constructs, potential IP &amp; pricing advantages<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>HWS117 is among the first domestically developed <strong>Class\u202f1 long\u2011acting FSH<\/strong> candidates, positioning Humanwell to capture premium market share if clinical success is demonstrated.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-market-opportunity\">Strategic Outlook &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ART Market Growth<\/strong>: China\u2019s infertility rate is rising, with >1\u202fmillion ART cycles annually; FSH constitutes a <strong>\u00a54\u202fbillion<\/strong> (\u2248\u202fUS$560\u202fmillion) domestic market growing at <strong>>10\u202f% CAGR<\/strong>.<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: As a <strong>long\u2011acting Class\u202f1<\/strong> product, HWS117 may command favorable reimbursement and physician preference over biosimilar\u2011type Class\u202f3.2 agents.<\/li>\n\n\n\n<li><strong>Next Milestones<\/strong>: Humanwell plans to initiate <strong>Phase\u202f1\/2<\/strong> trials in <strong>Q1\u202f2026<\/strong>, with data expected by <strong>H2\u202f2027<\/strong> to support registrational pathway.<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Positive China data could enable out\u2011licensing or partnered entry into Southeast Asian and emerging markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding HWS117 development timelines, clinical outcomes, and market potential. Actual results may vary due to regulatory, clinical, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/600079_20251129_QXLG.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600079_20251129_QXLG.\"><\/object><a id=\"wp-block-file--media-8ecdae0e-1f11-4ecd-a34f-3a1e32ea99cb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/600079_20251129_QXLG.pdf\">600079_20251129_QXLG<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/600079_20251129_QXLG.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8ecdae0e-1f11-4ecd-a34f-3a1e32ea99cb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class\u202f1 biological product HWS117 injection&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49663,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,266,1098],"class_list":["post-49660","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-humanwell-healthcare","tag-sha-600079"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Humanwell&#039;s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class\u202f1 biological product HWS117 injection has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for controlled ovarian stimulation in assisted reproductive technology (ART).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49660\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Humanwell&#039;s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction\" \/>\n<meta property=\"og:description\" content=\"Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class\u202f1 biological product HWS117 injection has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for controlled ovarian stimulation in assisted reproductive technology (ART).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49660\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-01T15:15:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T15:15:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Humanwell&#8217;s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction\",\"datePublished\":\"2025-12-01T15:15:03+00:00\",\"dateModified\":\"2025-12-01T15:15:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0106.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Humanwell Healthcare\",\"SHA: 600079\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49660#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49660\",\"name\":\"Humanwell's HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0106.webp\",\"datePublished\":\"2025-12-01T15:15:03+00:00\",\"dateModified\":\"2025-12-01T15:15:04+00:00\",\"description\":\"Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class\u202f1 biological product HWS117 injection has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for controlled ovarian stimulation in assisted reproductive technology (ART).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49660\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0106.webp\",\"width\":1080,\"height\":608,\"caption\":\"Humanwell's HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49660#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Humanwell&#8217;s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Humanwell's HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction - Insight, China&#039;s Pharmaceutical Industry","description":"Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class\u202f1 biological product HWS117 injection has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for controlled ovarian stimulation in assisted reproductive technology (ART).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49660","og_locale":"en_US","og_type":"article","og_title":"Humanwell's HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction","og_description":"Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class\u202f1 biological product HWS117 injection has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for controlled ovarian stimulation in assisted reproductive technology (ART).","og_url":"https:\/\/flcube.com\/?p=49660","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-01T15:15:03+00:00","article_modified_time":"2025-12-01T15:15:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49660#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49660"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Humanwell&#8217;s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction","datePublished":"2025-12-01T15:15:03+00:00","dateModified":"2025-12-01T15:15:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49660"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49660#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0106.webp","keywords":["Clinical trial approval \/ initiation","Humanwell Healthcare","SHA: 600079"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49660#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49660","url":"https:\/\/flcube.com\/?p=49660","name":"Humanwell's HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49660#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49660#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0106.webp","datePublished":"2025-12-01T15:15:03+00:00","dateModified":"2025-12-01T15:15:04+00:00","description":"Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class\u202f1 biological product HWS117 injection has received clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for controlled ovarian stimulation in assisted reproductive technology (ART).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49660#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49660"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49660#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0106.webp","width":1080,"height":608,"caption":"Humanwell's HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49660#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Humanwell&#8217;s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49660"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49660\/revisions"}],"predecessor-version":[{"id":49664,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49660\/revisions\/49664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49663"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}